|
|
Vol. 11.18 – 19 October, 2026
|
|
|
|
|
|
|
|
|
By integrating mitochondrial proteome annotations with mouse and human transcriptomic datasets, scientists identified Coenzyme Q10a, a striated muscle-enriched mitochondrial protein, as a regulator of postnatal cardiac growth. [Proceedings of the National Academy of Sciences of the United States of America]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
|
|
Researchers investigated the role and molecular mechanisms of OTUD5, a member of the deubiquitinase family, in pathological cardiac hypertrophy. OTUD5 expression is greatly increased in cardiomyocytes from hypertrophic hearts.
[Experimental & Molecular Medicine]
|
|
|
|
|
|
Investigators engineered large tubular constructs from hiPSC-derived cardiomyocytes and human foreskin fibroblasts via a rotating mold technology in four independent experiments.
[Biofabrication]
|
|
|
|
|
|
Scientists investigated the efficacy, safety window, and redox-regulatory mechanism of juglone, a naturally occurring 5-hydroxy-1,4-naphthoquinone.
[Pharmacological Research]
|
|
|
|
|
|
The authors identified aberrant cardiomyocyte cell cycle arrest as a previously unrecognized pathological driver of heart failure with preserved ejection fraction (HFpEF) that hinders tissue repair.
[Acta Pharmacologica Sinica]
|
|
|
|
|
|
Researchers aimed to identify a direct cardiac target of empagliflozin and define the downstream signaling mechanisms mediating its cardioprotective effects in diabetic cardiomyopathy.
[Diabetes & Metabolism Journal]
|
|
|
|
|
|
Investigators combined high-content morphological profiling, phospho-protein arrays, and systems modeling to characterize the diverse forms of hypertrophy induced by angiotensin II, endothelin-1, insulin growth factor-1, and neuregulin-1.
[Journal of Molecular and Cellular Cardiology]
|
|
|
|
|
|
Scientists performed RNA-sequencing and transcriptomic analysis on hearts from C57BL/6 J mice exposed to alcohol for ten weeks, and collected at two distinct circadian time points.
[Molecular and Cellular Biochemistry]
|
|
|
|
|
|
Researchers aimed to investigate whether exercise can influence heart failure progression by regulating expression of the lncRNA NEAT1, and to elucidate its molecular mechanisms.
[Molecular and Cellular Biochemistry]
|
|
|
|
|
|
|
|
Researchers used the SOD1G93A amyotrophic lateral sclerosis (ALS) mouse model and wild-type mice across the lifespan to generate an integrated single-nucleus transcriptomic atlas of skeletal muscle, mapping changes associated with ALS and aging.
[Proceedings of the National Academy of Sciences of the United States of America]
|
|
|
|
|
|
To test whether titin may be responsible for residual force enhancement, investigators used multiple titin immunolabels on single isolated myofibrils to approximately track the migration of individual titin segments in real-time.
[Proceedings of the National Academy of Sciences of the United States of America]
|
|
|
|
|
|
|
|
Researchers reported a 3D microfluidic-based tissue-engineered model with human brain smooth muscle cells (SMCs) forming a microvessel within a collagen I hydrogel. Using this platform, they demonstrated that serum-free culture conditions are essential to prevent SMC overproliferation. [ACS Biomaterials Science & Engineering]
|
|
|
|
|
|
|
|
In this review of current case reports of glucose-6-phosphate dehydrogenase deficiency, the authors explore whether the myocyte also undergoes a similar oxidative stress as a red blood cell. [Seminars in Perinatology]
|
|
|
|
|
|
|
|
Cytokinetics, Incorporated announced that Health Canada has issued a Notice of Compliance authorizing MYQORZO® (aficamten) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy of New York Heart Association class II-III in adult patients.
[Cytokinetics, Incorporated]
|
|
|
|
|
|
Epicrispr Biotechnologies announced that it has been awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM) to support the ongoing first-in-human clinical trial of EPI-321, the company’s epigenetic therapy for facioscapulohumeral muscular dystrophy (FSHD). [Epicrispr Biotechnologies (BusinessWire)]
|
|
|
|
|
|
|
|
November 5-7, 2026 Shenzhen, China
|
|
|
|
|
|
|
|
|
|
|
University of California Los Angeles – Los Angeles, California, United States
|
|
|
|
|
|
|
Human Technopole – Milan, Italy
|
|
|
|
|
|
|
University of Virginia – Charlottesville, Virginia, United States
|
|
|
|
|
|
|
Baylor College of Medicine – Houston, Texas, United States
|
|
|
|
|
|
|
University of Nebraska-Lincoln – Lincoln, Nebraska, United States
|
|
|
|
|
|